Asking the Right Questions About Cannabis Legalization
Tony George, MD, HS '96, an addiction specialist at the University of Toronto, believes that Canada has not prepared for legalization and its consequences. He argues that more research on the effects—positive and negative—of smoking pot is needed, as well as increased access to treatment for those who suffer from cannabis use disorder.
Yale researchers investigate decline in use of preventive defibrillators
In some patients with weak heart muscles, an implantable cardioverter defibrillator, or ICD, can help maintain normal heart rhythm and prolong life. However, concerns about possible overuse of these devices, and a federal investigation, may have led to a recent drop in their use by doctors, a Yale-led study found.
Viral Suppression Helps Lower Risk for Many Types of Cancer, Study Finds.
A new study by the Yale School of Public Health and partner institutions is the first to examine the potential cancer prevention benefits of prolonged periods of HIV viral suppression, resulting from antiretroviral therapy, for persons living with HIV.
New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies are adopted at a much quicker pace than is typical for newly approved medical treatments, the researchers said. However, patients receiving the therapies are older than those in the clinical trials used to evaluate them, pointing to a disconnect between research and practice that should be addressed, they noted.
Yale-developed plan to curb opioid overdose crisis helps state, nation
The opioid addiction and overdose epidemic continues to take the lives of too many Americans. Of the nearly 64,000 overdose deaths reported in 2016, almost two-thirds involved a prescription or illicit opioid. Yale faculty have confronted the crisis in myriad ways, including research that impacts policy and medical practice.
Big data analysis accurately predicts patient survival from heart failure
Heart failure is the leading cause of death and disability in the United States, costing healthcare systems worldwide more than $30 billion annually. Current approaches to treatment are limited by crude clinical assessments of the disease. In a new study, Yale researchers have successfully used big data methods to improve prediction of heart failure patient survival. They also described data-driven categories of patients that are distinct in their response to commonly used therapies.
McKee to serve as expert on medication-assisted treatment panel
Sherry McKee, PhD, Professor of Psychiatry, will be an expert panelist when two federal agencies convene January 29 and 30 in Maryland to discuss the implementation of a medication-assisted treatment (MAT) program for individuals involved in the criminal justice system.
Targeting Skyrocketing Drug Prices, Yale Students Prepare Roadmap for Lawmakers
The Yale Global Health Justice Partnership (GHJP), in collaboration with the National Physicians Alliance and the Universal Health Care Foundation of Connecticut, released a policy white paper, “Curbing Unfair Drug Prices: A Primer for States,” this week that seeks to advance state-level legislative efforts to rein in prescription drug prices by providing lawmakers with a clear picture of the strategies at their disposal.
YSPH Study Highlights Implications of Instability in Medicaid Markets
Millions of Americans with Medicaid coverage were affected when their insurance plans exited state Medicaid programs from 2006 to 2014, highlighting potential instability in these markets for Medicaid beneficiaries and the quality of care received, a new study led by the Yale School of Public Health finds.
Trump wants faster FDA action, but 1 in 3 drugs have safety issues after approval
President Trump wants the Food and Drug Administration to approve drugs faster, but researchers at the Yale School of Medicine found that nearly a third of medications that reached the market from 2001 through 2010 had major safety issues years after they became widely available to patients.Source: STAT
Ponce recognized for advocacy that exempted internship positions from federal hiring freeze
Allison N. Ponce, PhD, Associate Professor of Psychiatry, has been recognized with a citation from the American Psychological Association of Graduate Students (APAGS) for advocating to exempt more than 700 accredited internship positions from a federal hiring freeze.
Why Hospitals Need to Stop Boarding Patients in Emergency Rooms
Just after World War II, there were 1.4 million hospital beds available in the U.S. The most recent estimates show fewer than 900,000 beds, even though the nation’s population has grown by 120% over the same period. Better care delivery, technology, and changing financial incentives have driven much of this decrease, with hospitals continuing to downsize their staff and operations, making for less-flexible bed management. Also shrinking in number are emergency rooms (ERs), even while demand increases.Source: Wall Street Journal
FDA approves drugs more quickly than peer agency in Europe
The U.S. Food and Drug Administration (FDA) reviews and approves new medicines in a shorter timeframe than its peer agency in Europe, the European Medicines Agency (EMA), says a Yale researcher. This finding comes at a time when the FDA is under renewed pressure to streamline and speed up its approval process, and provides data to inform ongoing policy discussions.
Scientists Brace for a Lost Generation in American Research
Kelly Cosgrove, associate professor of psychiatry at Yale and Joy Hirsch, professor of psychiatry and neurobiology at the Yale School of Medicine weigh in on private funding not being enough to offset the president's proposed budget cuts for scientific research and medical research.Source: The Atlantic